On Tuesday, Veeva Systems Cl A earned an upgrade to its Relative Strength (RS) Rating, from 69 to 76.
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks tend to have an RS Rating of over 80 in the early stages of their moves. See if Veeva Systems Cl A can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
Veeva Systems Cl A is trying to complete a cup with handle with a 240.95 buy point. See if the stock can clear the breakout price in heavy trading.
The company posted 31% EPS growth in the latest quarterly report. Revenue rose 13%. Keep an eye out for the company's next round of numbers on or around Mar. 5.
Veeva Systems Cl A holds the No. 3 rank among its peers in the Computer Software-Medical industry group. Doximity is the top-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
